ClinicalTrials.gg
RecruitingNCT06353594COPERNICANUpdated Nov 20, 2026

Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI

An interventional study of Primary PCI in ST Elevation Myocardial Infarction, sponsored by Hospital Universitario La Fe. Recruiting at 23 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Hospital Universitario La Fe · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Nov 20, 2026Primary completion movedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,272
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies in ST Elevation Myocardial Infarction with a site in Spain — 4 open to participants now, 10 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Spain.

Planned enrollment
8th of 27
1,272 · median 450
Started
2024
the only one that year
No phase
16 of 41
1 open now
Registered
34th of 41
by date

Among the 41 studies in ST Elevation Myocardial Infarction with a site in Spain, this one is the 8th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2024, is one of 16 with no phase, and was the 34th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

4 of the 41 studies in ST Elevation Myocardial Infarction with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in ST Elevation Myocardial Infarction with a site in Spain, or all of them as a file.
02

Study summary

The objective is to compare a reduced stent strategy based on drug-coated balloon (DCB) percutaneous coronary intervention (PCI) with conventional drug-eluting stent (DES) coronary revascularization in patients presenting with ST-segment myocardial infarction (STEMI).

Randomization will be performed after successful culprit-lesion guidewire crossing and flow restoration. Random allocation in a 1:1 fashion to one of the following strategies:

  • Study group: reduced stent PCI strategy (DCB-based)
  • Control group: conventional PCI strategy (DES-based).
03

Conditions studied

  • ST Elevation Myocardial Infarction

Keywords

  • STEMI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Patients presenting with STEMI and indication to undergo pPCI.

Exclusion criteria

Exclusion Criteria:

  • \<1 year due 1 to non-cardiac disease.
  • Inability to provide .
  • Cardiogenic shock.
  • \<15%.
  • Left main disease.
  • Stent thrombosis
  • Patients with prior bypass graft lesions requiring PCI (culprit or non culprit lesions).
  • Patients with chronic total occlusions.
  • Untreatable coronary disease.
  • Non-identified culprit lesion.
  • Known allergy to aspirin, ticagrelor, prasugrel, clopidogrel, paclitaxel or sirolimus.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,272 participants (estimated)

Study arms

  • Experimental
    DCB-based

    Reduced stent PCI strategy: Culprit lesion revascularization with DCB will be performed after coronary predilation if residual stenosis ≤30%, lack of dissections \>type B and TIMI 3 flow. If the aforementioned culprit-lesion characteristics are not achieved after DCB-PCI, a DES will be implanted.

    Device: Primary PCI

  • No intervention
    DES-based

    Control group

Interventions

  • DevicePrimary PCI

    Coronary percutaneous revascularization

06

What researchers measure

Primary outcomes

  1. Target lesion failure (TLF)

    Target-vessel myocardial infarction or ischemia-driven target-lesion revascularization

    Time frame: 12 months

Secondary outcomes

  1. Incidence of all-cause death

    Physicians Assessment

    Time frame: 10 years

  2. Incidence of myocardial infarction

    Physicians Assessment

    Time frame: 10 years

  3. Incidence of cardiovascular death

    Physicians Assessment

    Time frame: 10 years

  4. Incidence of target lesion revascularization

    Physicians Assessment

    Time frame: 10 years

  5. Incidence of stent thrombosis

    Physicians Assessment

    Time frame: 10 years

  6. Incidence of acute vessel closure

    Physicians Assessment

    Time frame: 10 years

  7. Incidence of stroke

    Physicians Assessment

    Time frame: 10 years

  8. Incidence of acute kidney injury

    Physicians Assessment

    Time frame: 10 years

  9. Incidence of bleeding

    Physicians Assessment

    Time frame: 10 years

07

Study locations

23 of 23 sites recruiting
08

References and documents

Publications

  • Sanz-Sanchez J, Santos Martinez S, Rumiz Gonzalez E, Oteo Dominguez JF, Tejada Ponce D, Gomez Menchero A, Sanchez Elvira G, Fuertes Ferre G, Rivero Crespo F, Lukic Otanovic A, Diaz Fernandez J, Galindo Fernandez E, Urbano Carrillo C, Salvatella Giralt N, Torres Sanchez M, Garcia Touchard A, Ibanez Cabeza B, Stefanini G, Alfonso Manterola F, Garcia Garcia H, Amat-Santos IJ. Reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with STEMI: design of the COPERNICAN trial. Rev Esp Cardiol (Engl Ed). 2026 Feb;79(2):100-105. doi: 10.1016/j.rec.2025.05.005. Epub 2025 May 22. English, Spanish. PubMed 40412715 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2028, 48 months after the start.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 48 months is above that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Mar 2028, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Apr 9, 2024
StartActual
Mar 11, 2024
Primary completionEst.
Mar 2028was Sep 2026
CompletionEst.
Sep 2035
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Mar 2028
Nov 20, 2026
Sponsor
Collaborators added: ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Sep 2026→Mar 2028
    Sponsor Collaborators added: ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06353594
Lead sponsor
Hospital Universitario La Fe
Collaborators
ERA4Health, ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)
Responsible party
Jorge Sanz Sanchez (Principal Investigator, Hospital Universitario La Fe) — Principal investigator
First posted
Apr 9, 2024
Start date
Mar 11, 2024
Primary completion
Mar 2028 (estimated)
Completion
Sep 2035 (estimated)
Last update
Nov 20, 2026

Study contacts

Naiara García Lamas
Contact
naiara@pinvestiga.com
634213101
Marta Fernández Álvarez
Contact
marta@pinvestiga.com
604037828
Jorge Sanz Sánchez, PI
principal investigator · Hospital Universitario La Fe
Ignacio J Amat Santos, PI
principal investigator · Hospital Universitario de Valladolid

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion